I am a healthcare professional


Welcome to MEDICALLY. This website is a non-promotional international resource intended to facilitate transparent scientific exchange regarding developments in medical research and disease management. It is intended for healthcare professionals outside the United Kingdom (UK) and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Roche and Genentech do not support, endorse or recommend the unapproved use of any compound or service in your jurisdiction, including those discussed on this website.

Please refer to local product information for any medicinal products mentioned. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same. Healthcare professionals outside the US are required to register and log-in to access the full range of content available on this website.

By clicking on one of the healthcare professional buttons below, you acknowledge you have read and understood this message and that you are requesting access to MEDICALLY. If you are not a healthcare professional, please use the other links below to access information relevant to you.


We use cookies on this site to enable the site to function properly and to enhance your user experience. Cookies are files stored in your browser, which most websites use to personalize your web experience. Your information will only be used to provide information that is relevant to you. It will not be used for any other purpose. If you wish to restrict or block cookies, which are set on your device, then you can do this through your browser settings.

You can find out more about cookies by browsing our Privacy Policy.


For healthcare professionals in Another Country browse medically.roche.com.

Not a healthcare professional? For individuals outside the US, browse Roche's patient website or roche.com. For individuals in the US, browse gene.com.

External site

The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Leave site
Roche and Genentech at

2024 ASCO Annual Meeting

Coming soon
02:00 PM
Duration 3hrs Chicago USA
Ipatasertib in patients with AKT1/2/3 mutation-positive (AKTmut) tumors: TAPISTRY study
Thomas D, Daniele G, Kim J-E, Gadgeel S, Ahn E, Paz-Ares L, Prenen H, Chen D, Fang J, Wilson TR, Simmons B, Barlesi F
Duration 3hrs Chicago USA
MyTACTIC: activity of targeted therapy in patients (pts) with advanced solid tumors harboring specific biomarkers
Schwartzberg LS, Spigel DR, Vanderwalde A, Zuniga R, Hong J, Szado T, Yoo B, Passler L, Wong W, Darbonne WC, Daniel D
06:30 PM
08:00 PM
Duration 180mins S100bc / Live Stream
Glofitamab monotherapy in patients with heavily pretreated relapsed/refractory (R/R) mantle cell lymphoma (MCL): updated analysis from a Phase I/II study
Phillips T, Carlo-Stella C, Morschhauser F, Bachy E, Crump M, Trneny M, Bartlett NL, Zaucha J, Wrobel T, Offner F, Filezac de L'Etang A, Relf J, Carlile DJ, Byrne B, Mulvihill E, Lundberg L, Dickinson M
01:00 PM
Duration 180mins S100bc | Live Stream
Efficacy and safety of entrectinib▼ in children with extracranial solid or primary central nervous system (CNS) tumors harboring NTRK or ROS1 fusions
Desai A, Robinson G, Wu Y, Wang H, Basu E, Bagchi A, Casanova M, van Tilburg C, Campbell-Hewson Q, Armstrong AE, Andre N, Devlin CE, Wulff J, Cardenas A, Meneses-Lorente G, Hutchinson KE, Lian Q, Ryklansky C, Fox E, Gajjar A
02:00 PM
Duration 3hrs Chicago USA
Association of machine learning (ML) derived histological features with transcriptomics based molecular subtypes in advanced renal cell carcinoma (RCC)
Niha Beig, Shima Nofallah, David McDermott, Robert Motzer, Thomas Powles, Brian Rini, Hartmut Koeppen, Romain Banchereau, Miles Markey, Isaac Finberg2, Geetika Singh2, Lauren Brunner2, Robert Egger2, Chintan Parmer, Jake Conway, Stephanie Hennek, Dan Ruderman, Samuel Vilchez, Mahrukh Huseni, Jennifer Giltnane
Duration 3hrs Chicago USA
INAVO122: A Phase III study of maintenance inavolisib or placebo + pertuzumab + trastuzumab following induction with pertuzumab + trastuzumab + a taxane in patients (pts) with PIK3CA-mutated, HER2-positive advanced breast cancer (HER2+ aBC)
Swain S, Barrios C, Basho R, Curigliano G, Harbeck N, Huang CS, Karmo M, Loi S, Tolaney S,Turner N, Collier A, Henschel V, Swat A, Warburton S, Amair-Pinedo F, Corts J
03:00 PM
01:00 PM
Duration 180mins Arie Crown Theater | Live Stream
Health-related quality of life (HRQoL) results for adjuvant alectinib vs chemotherapy in patients with resected ALK+ non-small cell lung cancer (NSCLC): data from ALINA
Nishio M, Wu Y-L, Barlesi F, Ahn JS, Lee DH, Lee J-S, Zhong W, Horinouch H, Hockmair M, Tanaka H, Glogowski M, Rittmeyer A, Filder M, Wrona A, Mamolo C, Cardona A, Ruf F, Smoljanovic V, Solomon BJ
Duration 180mins Arie Crown Theatre
BEAT-SC: A randomized Phase III study of bevacizumab or placebo in combination with atezolizumab, chemotherapy and etoposide in patients with extensive-stage small cell lung cancer (ES-SCLC)
Yuichiro Ohe, Makoto Nishio , Baohui Han, Satoshi Watanabe, Xiubao Ren, Shuji Murakami, Nong Yang, Isamu Okamoto, Gaofeng Li, Nobuyuki Katakami, Xianling Liu, Naoyuki Nogami, Yuki Nakagawa, Morihiko Hayashi, Toshihiro Nanki, Chunyu Qian, Nobuyuki Yamamoto
Duration 90mins Chicago, USA
Circulating KIM-1 biomarker analysis in IMmotion010, a randomized Phase 3 study of adjuvant atezolizumab (atezo) vs placebo (pbo) in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
Laurence Albiges, Axel Bex, Cristina Suarez, Robert Uzzo, Xiaobin Tang, Zoe June Assaf, Sarita Dubey, Erik Goluboff, Corey Carter, Romain Banchereau, Mahrukh Huseni, Sumanta Pal, Brian Rini
02:00 PM
Duration 3hrs Chicago USA
Glofitamab monotherapy retreatment in patients with heavily pre-treated relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL): results from a Phase I/II study
Bartlett NL, Dickinson M, Hutchings M, Carlo-Stella C, Wu S-J, Leppa S, Trneny M, Corradini P, Offner F, Mulvihill E, Bottos A, Tchaleu FB, Baumlin P, Relf J, Lundberg L, Bachy E
Duration 3hrs Chicago USA
Real-world patient outcomes in biomarker-selected early non-small cell lung cancer patients
Fawzi Abu Rous, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, Shirish Gadgeel
Duration 3hrs Chicago USA
Genomic profiling in a subgroup analysis of patients (pts) with diffuse large B-cell lymphoma (DLBCL) and extranodal (EN) sites of involvement in the Phase III Pola-R-CHP vs R-CHOP (POLARIX) study
Lue JK, Morschhauser F, Tilly H, Lenz G, Jardin F, Herrera AF, Sharman JP, Flowers CR, Friedberg JW, Trněný M, Herbaux C, Yan M, Jiang Y, Hirata JH, Batlevi CL, Sugidono M, Sahin D, Leung W, Harris W, Salles G, Sehn LH
Duration 3hrs Chicago USA
Mosunetuzumab with polatuzumab vedotin: subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)
Assouline S, Budde LE, Chavez JC, Diefenbach C, Dorritie K, Ghosh N, Olszewski AJ, Lossos IS, Mehta A, Modi D, Naik S, Smith SD, Makadia S, Pham S, Wu H, Batlevi CL, To I, Wei MC, Kamdar M
06:30 PM
Duration 3hrs Chicago USA
Krascendo-170 Lung: A phase Ib/II study of divarasib + pembrolizumab ± platinum-based chemotherapy and pemetrexed in untreated KRAS G12C+ advanced non-small cell lung cancer (NSCLC)
Skoulidis F, Cuppens K, Sacher A, Velcheti V, Lee D-H, Lin MT, Fernando TM, Li S, Bradley D, Zarak Crnkovic M, Mathisen M
Duration 3hrs Chicago USA
ALK testing patterns in early non-small cell lung cancer: A real-world evidence study
Ticeana Leal, Jesse Sussell, Celina Ngiam Kochounian, Qing Zhang, Thomas Majda, Danny Sheinson, Sarika Ogale, Ilze Bara, Katja Schulze, Jason Porter
Duration 3hrs Chicago USA
Budget Impact Model of LungFlag™, a Predictive Risk Model for Lung Cancer Screening
Michael K. Gould, Eran Choman, Nicolò Olghi, Milan Obradovic, Sarika Ogale, Carolina Heuser Sanmartin
Duration 3hrs Chicago USA
IMpower010: Disease-Free Survival Final Analysis and Second Overall Survival Interim Analysis Results After ≥5 years of Follow-up of a Phase III Study of Adjuvant Atezolizumab vs Best Supportive Care in Resected Stage IB-IIIA Non-Small Cell Lung Cancer
Heather A. Wakelee, Nasser Altorki, Caicun Zhou, Tibor Csőszi, Ihor O. Vynnychenko, Oleksandr Goloborodko, Achim Rittmeyer, Martin Reck, Alex Martinez-Marti, Hirotsugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, Chenqi Fu, Marcus Ballinger, Yu Deng, Minu K. Srivastava, Elizabeth Bennett, Barbara J. Gitlitz, Enriqueta Felip
Duration 3hrs Chicago USA
J-TAIL-2: A prospective observational study of atezolizumab (atezo) combination therapy in patients with non-small cell lung cancer (NSCLC) in Japan
Yasutaka Watanabe, Makoto Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi, Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Masafumi Yamaguchi, Kozo Yoshimori, Masahiro Seike, Hironori Yoshida, Kazumi Nishino, Asako Miwa, Misa Tanaka, Akihiko Gemma
Duration 3hrs Chicago USA
J-TAIL-2: A prospective, observational study of atezolizumab (atezo) combined with carboplatin and etoposide (CE) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) in Japan
Ryota Saito, Masato Nishio, Kadoaki Ohashi, Atsushi Osoegawa, Eiki Kikuchi, Hideharu Kimura, Yasushi Goto, Junichi Shimizu, Eisaku Miyauchi,Hiroshige Yoshioka, Ichiro Yoshino, Toshihiro Misumi, Takashi Kijima, Kenichi Chikamori, Hisashi Tanaka, Kazunori Tobino, Tatsuro Fukuhara, Hirotaka Kuroki, Misa Tanaka, Akihiko Gemma
01:00 PM
Duration 90mins S406 | On Demand
Atezolizumab in patients with tumor mutational burden-high (TMB) tumors from the TAPISTRY trial
Dziadziuszko R, Barlesi F, Kim J-E, Gadgeel S, Krzakowski M, Jeong J-H, Daniele G, Chen, D, Hu Y, Wilson T, Simmons B, Thomas D